These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30268702)

  • 41. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
    Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
    Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
    Hu J; Wang Y; Li Y; Cao D; Xu L; Song S; Damaneh MS; Li J; Chen Y; Wang X; Chen L; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2018 Apr; 150():156-175. PubMed ID: 29525435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.
    Liu Z; Chen H; Wang P; Li Y; Wold EA; Leonard PG; Joseph S; Brasier AR; Tian B; Zhou J
    J Med Chem; 2020 May; 63(10):5242-5256. PubMed ID: 32255647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyronaridine as a Bromodomain-Containing Protein 4-
    Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.
    Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C
    Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
    Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
    J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign.
    Colarusso E; Gazzillo E; Boccia E; Terracciano S; Bruno I; Bifulco G; Chini MG; Lauro G
    Molecules; 2024 Aug; 29(17):. PubMed ID: 39274873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biased multicomponent reactions to develop novel bromodomain inhibitors.
    McKeown MR; Shaw DL; Fu H; Liu S; Xu X; Marineau JJ; Huang Y; Zhang X; Buckley DL; Kadam A; Zhang Z; Blacklow SC; Qi J; Zhang W; Bradner JE
    J Med Chem; 2014 Nov; 57(21):9019-27. PubMed ID: 25314271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.
    Ayoub AM; Hawk LML; Herzig RJ; Jiang J; Wisniewski AJ; Gee CT; Zhao P; Zhu JY; Berndt N; Offei-Addo NK; Scott TG; Qi J; Bradner JE; Ward TR; Schönbrunn E; Georg GI; Pomerantz WCK
    J Med Chem; 2017 Jun; 60(12):4805-4817. PubMed ID: 28535045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
    Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
    Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4.
    Zhong H; Wang Z; Wang X; Liu H; Li D; Liu H; Yao X; Hou T
    Phys Chem Chem Phys; 2019 Dec; 21(45):25276-25289. PubMed ID: 31701109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 4-Methyl-1,2,3-Triazoles as
    Cui H; Carlson AS; Schleiff MA; Divakaran A; Johnson JA; Buchholz CR; Zahid H; Vail NR; Shi K; Aihara H; Harki DA; Miller GP; Topczewski JJ; Pomerantz WCK
    J Med Chem; 2021 Jul; 64(14):10497-10511. PubMed ID: 34236185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.
    Vidler LR; Filippakopoulos P; Fedorov O; Picaud S; Martin S; Tomsett M; Woodward H; Brown N; Knapp S; Hoelder S
    J Med Chem; 2013 Oct; 56(20):8073-88. PubMed ID: 24090311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SARS-CoV-2 envelope protein attain K
    Agrahari AK; Srivastava M; Singh M; Asthana S
    J Biomol Struct Dyn; 2023; 41(24):15305-15319. PubMed ID: 36907648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
    Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
    Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
    Yoo M; Park TH; Yoo M; Kim Y; Lee JY; Lee KM; Ryu SE; Lee BI; Jung KY; Park CH
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.